We are live on
!
Find out more
5VM
5AM Venture Management Portfolio holdings
AUM
$288M
1-Year Est. Return
313.93%
This Fund
S&P 500
This Quarter
Est. Return
+71.58%
1 Year Est. Return
+313.93%
3 Year Est. Return
+546.33%
5 Year Est. Return
+596.42%
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$42.1M
(+13%)
Cap. Flow
-$52.8M
Cap. Flow
% of AUM
-14.65%
Top 10 Holdings %
Top 10 Hldgs %
79.82%
Holding
22
New
1
Increased
–
Reduced
2
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALX Oncology
ALXO
|
+$5.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viridian Therapeutics
VRDN
|
+$22.9M |
| 2 |
Erasca
ERAS
|
+$22.7M |
| 3 |
Enliven Therapeutics
ELVN
|
+$11.9M |
| 4 |
Rallybio
RLYB
|
+$1.11M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Erasca
ERAS
$6.43B
| $56.4M | 15.66% |
3,485,971
-1,919,433
| -36% | -$22.7M |
|
2
Entrada Therapeutics
TRDA
$290M
| $51.2M | 14.21% |
4,056,379
| – | – |
|
3
Tyra Biosciences
TYRA
$1.51B
| $39.4M | 10.94% |
1,029,298
| – | – |
|
4
CAMP4 Therapeutics
CAMP
$341M
| $25.9M | 7.19% |
5,869,091
| – | – |
|
|
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
| $23.1M | 6.41% |
580,945
| – | – |
|
6
Pharvaris
PHVS
$2.46B
| $22.5M | 6.26% |
797,600
| – | – |
|
|
MPLT
7
MapLight Therapeutics
MPLT
$545M
| $19.3M | 5.36% |
950,011
| – | – |
|
|
TECX
8
Tectonic Therapeutic
TECX
$682M
| $18.8M | 5.21% |
606,660
| – | – |
|
9
Celldex Therapeutics
CLDX
$3.29B
| $15.8M | 4.38% |
497,270
| – | – |
|
|
ARTV
10
Artiva Biotherapeutics
ARTV
$560M
| $15.2M | 4.21% |
2,353,304
| – | – |
|
11
EyePoint Inc
EYPT
$1.27B
| $13.5M | 3.76% |
1,050,000
| – | – |
|
12
Surrozen
SRZN
$282M
| $11.3M | 3.13% |
387,500
| – | – |
|
13
Zentalis Pharmaceuticals
ZNTL
$255M
| $9.24M | 2.56% |
3,947,913
| – | – |
|
14
GH Research
GHRS
$2.02B
| $8.05M | 2.24% |
572,665
| – | – |
|
15
Protara Therapeutics
TARA
$235M
| $7.14M | 1.98% |
1,369,782
| – | – |
|
16
Biohaven
BHVN
$2.21B
| $6.25M | 1.74% |
738,972
| – | – |
|
|
17
ALX Oncology
ALXO
$271M
| $6.13M | 1.7% |
+3,057,325
| New | +$5.82M |
|
18
Skye Bioscience
SKYE
$17.6M
| $5.95M | 1.65% |
9,681,763
| – | – |
|
|
19
Rallybio
RLYB
$90.2M
| $2.62M | 0.73% |
291,788
-162,053
| -36% | -$1.11M |
|
|
SLN
20
Silence Therapeutics
SLN
$648M
| $2.51M | 0.7% |
476,200
| – | – |
|
|
21
Enliven Therapeutics
ELVN
$4.31B
| – | – |
-772,477
| Closed | -$11.9M |
|
|
22
Viridian Therapeutics
VRDN
$2.5B
| – | – |
-736,595
| Closed | -$22.9M |
|
Similar funds
TA
APW
RCS
FH
IAMOG
MP
OL
CWA
5AM Venture Management's Q1 2026 Portfolio in Review
As of Q1 2026, 5AM Venture Management held 22 positions worth $360M, up 13% from $318M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
5AM Venture Management withdrew a net $52.8M in Q1 2026, closing 2 positions and reducing 2 holdings. Its most notable exit was Viridian Therapeutics, an estimated $22.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, 5AM Venture Management opened a new position in ALX Oncology worth $6.13M.
- 5AM Venture Management's largest Q1 2026 buy was ALX Oncology: 3,057,325 shares worth $6.13M.
- 5AM Venture Management's biggest Q1 2026 reduction was Erasca, cutting an estimated $22.7M.
- 5AM Venture Management fully exited Viridian Therapeutics in Q1 2026, selling an estimated $22.9M.
- 5AM Venture Management's ten largest holdings make up 80% of its $360M portfolio in Q1 2026.
- 5AM Venture Management opened 1 new position and closed 2 in Q1 2026.
- 5AM Venture Management's portfolio value rose 13% quarter-over-quarter to $360M.
Based on 5AM Venture Management's 13F filing for Q1 2026, filed 15 May 2026.